Skip to main content
Top
Published in: Endocrine Pathology 4/2021

01-12-2021 | Neuroendocrine Tumor

Middle Ear “Adenoma”: a Neuroendocrine Tumor with Predominant L Cell Differentiation

Published in: Endocrine Pathology | Issue 4/2021

Login to get access

Abstract

This morphological and immunohistochemical study demonstrates that tumors currently known as “middle ear adenomas” are truly well-differentiated epithelial neuroendocrine tumors (NETs) composed of cells comparable to normal intestinal L cells, and therefore, these tumors resemble hindgut NETs. These tumors show consistent expression of glucagon, pancreatic polypeptide, PYY, and the transcription factor SATB2, as well as generic neuroendocrine markers and keratins. The same L cell markers are expressed by cells within the normal middle ear epithelium. These markers define a valuable immunohistochemical profile that can be used for differential diagnosis of middle ear neoplasms, particularly in distinguishing epithelial NETs from paragangliomas. The discovery of neuroendocrine cells expressing the same markers in non-neoplastic middle ear mucosa opens new areas of investigation into the physiology of the normal middle ear and the pathophysiology of middle ear disorders.
Literature
1.
go back to reference Hyams VJ, Michaels L. Benign adenomatous neoplasm (adenoma) of the middle ear. Clin Otolaryngol Allied Sci 1976;1(1):17-26.CrossRef Hyams VJ, Michaels L. Benign adenomatous neoplasm (adenoma) of the middle ear. Clin Otolaryngol Allied Sci 1976;1(1):17-26.CrossRef
2.
go back to reference Riches WG, Johnston WH. Primary adenomatous neoplasms of the middle ear: light and electron microscopic features of a group distinct from the ceruminomas. Am J Clin Pathol 1982 Feb;77(2):153-61.CrossRef Riches WG, Johnston WH. Primary adenomatous neoplasms of the middle ear: light and electron microscopic features of a group distinct from the ceruminomas. Am J Clin Pathol 1982 Feb;77(2):153-61.CrossRef
3.
go back to reference Kochilas X, Birchall JP, Sloan P. Light and electron microscopic studies of a case of middle ear adenoma. Laryngoscope 1984 Nov;94(11 Pt 1):1482-4.PubMed Kochilas X, Birchall JP, Sloan P. Light and electron microscopic studies of a case of middle ear adenoma. Laryngoscope 1984 Nov;94(11 Pt 1):1482-4.PubMed
4.
go back to reference McNutt MA, Bolen JW. Adenomatous tumor of the middle ear. An ultrastructural and immunocytochemical study. Am J Clin Pathol 1985 Oct;84(4):541–7. McNutt MA, Bolen JW. Adenomatous tumor of the middle ear. An ultrastructural and immunocytochemical study. Am J Clin Pathol 1985 Oct;84(4):541–7.
5.
go back to reference Bailey QR, Weiner JM. Middle ear adenoma: a case report with ultrastructural findings. J Laryngol Otol 1986 Apr;100(4):467-70.CrossRef Bailey QR, Weiner JM. Middle ear adenoma: a case report with ultrastructural findings. J Laryngol Otol 1986 Apr;100(4):467-70.CrossRef
6.
go back to reference Ketabchi S, Massi D, Franchi A, Vannucchi P, Santucci M. Middle ear adenoma is an amphicrine tumor: why call it adenoma? Ultrastruct Pathol 2001 Jan;25(1):73-8.CrossRef Ketabchi S, Massi D, Franchi A, Vannucchi P, Santucci M. Middle ear adenoma is an amphicrine tumor: why call it adenoma? Ultrastruct Pathol 2001 Jan;25(1):73-8.CrossRef
7.
go back to reference Torske KR, Thompson LD. Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature. Mod Pathol 2002 May;15(5):543-55.CrossRef Torske KR, Thompson LD. Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature. Mod Pathol 2002 May;15(5):543-55.CrossRef
8.
go back to reference Angouridakis N, Hytiroglou P, Markou K, Bouzakis A, Vital V. Middle ear adenoma/carcinoid tumour: a case report and review of the literature. Rev Laryngol Otol Rhinol (Bord ) 2009;130(3):199-202. Angouridakis N, Hytiroglou P, Markou K, Bouzakis A, Vital V. Middle ear adenoma/carcinoid tumour: a case report and review of the literature. Rev Laryngol Otol Rhinol (Bord ) 2009;130(3):199-202.
9.
go back to reference Saliba I, Evrard AS. Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series. Cases J 2009 Mar 13;2:6508.CrossRef Saliba I, Evrard AS. Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series. Cases J 2009 Mar 13;2:6508.CrossRef
10.
go back to reference Pontico M, Frantellizzi V, Cosma L, De VG. 111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME). Indian J Radiol Imaging 2020 Jul;30(3):400-4.CrossRef Pontico M, Frantellizzi V, Cosma L, De VG. 111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME). Indian J Radiol Imaging 2020 Jul;30(3):400-4.CrossRef
11.
go back to reference van der Lans RJL, Engel MSD, Rijken JA, Hensen EF, Bloemena E, van der Torn M, Leemans CR, Smit CFGM. Neuroendocrine neoplasms of the middle ear: Unpredictable tumor behavior and tendency for recurrence. Head Neck 2021 Feb 19. van der Lans RJL, Engel MSD, Rijken JA, Hensen EF, Bloemena E, van der Torn M, Leemans CR, Smit CFGM. Neuroendocrine neoplasms of the middle ear: Unpredictable tumor behavior and tendency for recurrence. Head Neck 2021 Feb 19.
12.
go back to reference Pellini R, Ruggieri M, Pichi B, Covello R, Danesi G, Spriano G. A case of cervical metastases from temporal bone carcinoid. Head Neck 2005 Jul;27(7):644-7.CrossRef Pellini R, Ruggieri M, Pichi B, Covello R, Danesi G, Spriano G. A case of cervical metastases from temporal bone carcinoid. Head Neck 2005 Jul;27(7):644-7.CrossRef
13.
go back to reference Ramsey MJ, Nadol JB, Jr., Pilch BZ, McKenna MJ. Carcinoid tumor of the middle ear: clinical features, recurrences, and metastases. Laryngoscope 2005 Sep;115(9):1660-6.CrossRef Ramsey MJ, Nadol JB, Jr., Pilch BZ, McKenna MJ. Carcinoid tumor of the middle ear: clinical features, recurrences, and metastases. Laryngoscope 2005 Sep;115(9):1660-6.CrossRef
14.
go back to reference Bell D, El-Naggar AK, Gidley PW. Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch 2017 Nov;471(5):667-72.CrossRef Bell D, El-Naggar AK, Gidley PW. Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch 2017 Nov;471(5):667-72.CrossRef
15.
go back to reference Marinelli JP, Cass SP, Mann SE, Haynes DS, Hunter JB, Isaacson B, Sweeney AD, Pelosi S, Willcox TO, O'Connell BP, Rivera M, Lane JI, Carlson ML. Adenomatous Neuroendocrine Tumors of the Middle Ear: A Multi-institutional Investigation of 32 Cases and Development of a Staging System. Otol Neurotol 2018 Sep;39(8):e712-e721.CrossRef Marinelli JP, Cass SP, Mann SE, Haynes DS, Hunter JB, Isaacson B, Sweeney AD, Pelosi S, Willcox TO, O'Connell BP, Rivera M, Lane JI, Carlson ML. Adenomatous Neuroendocrine Tumors of the Middle Ear: A Multi-institutional Investigation of 32 Cases and Development of a Staging System. Otol Neurotol 2018 Sep;39(8):e712-e721.CrossRef
16.
go back to reference Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018 Dec;31(12):1770-86.CrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018 Dec;31(12):1770-86.CrossRef
17.
go back to reference Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S., Grossman AB, Ezzat S. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol. In press 2021. Asa S.L., Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S., Grossman AB, Ezzat S. Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Mod Pathol. In press 2021.
18.
go back to reference Agaimy A, Lell M, Schaller T, Markl B, Hornung J. 'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathology 2015 Jan;66(2):182-91.CrossRef Agaimy A, Lell M, Schaller T, Markl B, Hornung J. 'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathology 2015 Jan;66(2):182-91.CrossRef
19.
go back to reference Garaud JC, Eloy R, Moody AJ, Stock C, Grenier JF. Glucagon- and glicentin-immunoreactive cells in the human digestive tract. Cell Tissue Res 1980;213:121-36.CrossRef Garaud JC, Eloy R, Moody AJ, Stock C, Grenier JF. Glucagon- and glicentin-immunoreactive cells in the human digestive tract. Cell Tissue Res 1980;213:121-36.CrossRef
20.
go back to reference Colony PC, Helmstaedter V, Moody AJ, Garaud JC, Forssmann WG. Glucagon and glicentin immunoreactive cells in human colon. Cell Tissue Res 1982;221:483-91.CrossRef Colony PC, Helmstaedter V, Moody AJ, Garaud JC, Forssmann WG. Glucagon and glicentin immunoreactive cells in human colon. Cell Tissue Res 1982;221:483-91.CrossRef
21.
go back to reference Böttcher G, Sjölund K, Ekblad E, Håkanson R, Schwartz TW, Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept 1984;8:261-6.CrossRef Böttcher G, Sjölund K, Ekblad E, Håkanson R, Schwartz TW, Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept 1984;8:261-6.CrossRef
22.
go back to reference Böttcher G, Alumets J, Håkanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986;13:283-91.CrossRef Böttcher G, Alumets J, Håkanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986;13:283-91.CrossRef
23.
go back to reference Sohn JH, Cho MY, Park Y, Kim H, Kim WH, Kim JM, Jung ES, Kim KM, Lee JH, Chan HK, Park DY, Joo M, Kim S, Moon WS, Kang MS, Jin SY, Kang YK, Yoon SO, Han H, Choi E. Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. Cancer Res Treat 2015 Oct;47(4):813-22.CrossRef Sohn JH, Cho MY, Park Y, Kim H, Kim WH, Kim JM, Jung ES, Kim KM, Lee JH, Chan HK, Park DY, Joo M, Kim S, Moon WS, Kang MS, Jin SY, Kang YK, Yoon SO, Han H, Choi E. Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. Cancer Res Treat 2015 Oct;47(4):813-22.CrossRef
24.
go back to reference Kim JY, Kim KS, Kim KJ, Park IJ, Lee JL, Myung SJ, Park Y, Park YS, Yu CS, Kim JC, Yu E, Jang HJ, Hong SM. Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis. Am J Surg Pathol 2015 May;39(5):632-43.CrossRef Kim JY, Kim KS, Kim KJ, Park IJ, Lee JL, Myung SJ, Park Y, Park YS, Yu CS, Kim JC, Yu E, Jang HJ, Hong SM. Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis. Am J Surg Pathol 2015 May;39(5):632-43.CrossRef
25.
go back to reference Li Z, Yuan J, Wei L, Zhou L, Mei K, Yue J, Gao H, Zhang M, Jia L, Kang Q, Huang X, Cao D. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors. Int J Clin Exp Pathol 2015;8(6):7072-82.PubMedPubMedCentral Li Z, Yuan J, Wei L, Zhou L, Mei K, Yue J, Gao H, Zhang M, Jia L, Kang Q, Huang X, Cao D. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors. Int J Clin Exp Pathol 2015;8(6):7072-82.PubMedPubMedCentral
26.
go back to reference Zhao LH, Chen C, Mao CY, Xiao H, Fu P, Xiao HL, Wang G. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors. Pathol Res Pract 2019 Jul;215(7):152448.CrossRef Zhao LH, Chen C, Mao CY, Xiao H, Fu P, Xiao HL, Wang G. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors. Pathol Res Pract 2019 Jul;215(7):152448.CrossRef
27.
go back to reference Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology 2020 Jan;76(2):251-64.CrossRef Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology 2020 Jan;76(2):251-64.CrossRef
28.
go back to reference Hoskoppal D, Epstein JI, Gown AM, Arnold Egloff SA, Gordetsky JB, Shi CJ, Giannico GA. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology 2020 Mar;76(4):550-9.CrossRef Hoskoppal D, Epstein JI, Gown AM, Arnold Egloff SA, Gordetsky JB, Shi CJ, Giannico GA. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology 2020 Mar;76(4):550-9.CrossRef
29.
go back to reference Tischler AS, Asa SL. Paraganglia. In: Mills SE, editor. Histology for Pathologists.Philadelphia: Wolters Kluwer; 2018. Tischler AS, Asa SL. Paraganglia. In: Mills SE, editor. Histology for Pathologists.Philadelphia: Wolters Kluwer; 2018.
30.
go back to reference Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018 Sep 13;7(9). Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med 2018 Sep 13;7(9).
31.
go back to reference Turchini J, Cheung VKY, Tischler AS, de Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 2018 Jan;72(1):97-105.CrossRef Turchini J, Cheung VKY, Tischler AS, de Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology 2018 Jan;72(1):97-105.CrossRef
32.
go back to reference Mete O, Pakbaz S, Lerario AM, Giordano TJ, Asa SL. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. Am J Surg Pathol 2021 Apr 8. Mete O, Pakbaz S, Lerario AM, Giordano TJ, Asa SL. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. Am J Surg Pathol 2021 Apr 8.
33.
go back to reference Ryan AF, Nasamran CA, Pak K, Draf C, Fisch KM, Webster N, Kurabi A. Single-Cell Transcriptomes Reveal a Complex Cellular Landscape in the Middle Ear and Differential Capacities for Acute Response to Infection. Front Genet 2020;11:358.CrossRef Ryan AF, Nasamran CA, Pak K, Draf C, Fisch KM, Webster N, Kurabi A. Single-Cell Transcriptomes Reveal a Complex Cellular Landscape in the Middle Ear and Differential Capacities for Acute Response to Infection. Front Genet 2020;11:358.CrossRef
34.
go back to reference van Waegeningh HF, Ebbens FA, van SE, Oostra RJ. Single origin of the epithelium of the human middle ear. Mech Dev 2019 Aug;158:103556. van Waegeningh HF, Ebbens FA, van SE, Oostra RJ. Single origin of the epithelium of the human middle ear. Mech Dev 2019 Aug;158:103556.
35.
go back to reference Hentzer E. Ultrastructure of the middle ear mucosa. Acta Otolaryngol Suppl 1984;414:19-27.CrossRef Hentzer E. Ultrastructure of the middle ear mucosa. Acta Otolaryngol Suppl 1984;414:19-27.CrossRef
Metadata
Title
Middle Ear “Adenoma”: a Neuroendocrine Tumor with Predominant L Cell Differentiation
Publication date
01-12-2021
Published in
Endocrine Pathology / Issue 4/2021
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-021-09684-z

Other articles of this Issue 4/2021

Endocrine Pathology 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.